4
Changes in Ownership
Xenon Pharmaceuticals Inc. Filed Acc 0000950170-25-009388
PRESIDENT & CEO sold 55,000 shares at an average $40.25 ($2,213,997)
- PRESIDENT & CEO acquired 55,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
MORTIMER IAN · PRESIDENT & CEO
Table I: Non-derivative
8 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-01-23 | Exercise or conversion : show line 1 in the form 10b5-1 | +16,217 | $17.76 | $288,014 | 47,519 | D |
| 2025-01-23 | Sale : show line 2 in the form 10b5-1 | −16,217 | $40.08 | $649,977 | 31,302 | D |
| 2025-01-24 | Exercise or conversion : show line 3 in the form 10b5-1 | +22,468 | $17.76 | $399,032 | 53,770 | D |
| 2025-01-24 | Sale : show line 4 in the form 10b5-1 | −22,468 | $40.20 | $903,214 | 31,302 | D |
| 2025-01-27 | Exercise or conversion : show line 5 in the form 10b5-1 | +15,166 | $17.76 | $269,348 | 46,468 | D |
| 2025-01-27 | Sale : show line 6 in the form 10b5-1 | −15,166 | $40.46 | $613,616 | 31,302 | D |
| 2025-01-27 | Exercise or conversion : show line 7 in the form 10b5-1 | +1,149 | $17.76 | $20,406 | 32,451 | D |
| 2025-01-27 | Sale : show line 8 in the form 10b5-1 | −1,149 | $41.07 | $47,189 | 31,302 | D |
| Open-market sales · 55,000 sh · avg $40.25 · $2,213,997 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2025-01-23 | Exercise or conversion : show line 9 in the form 10b5-1 Stock Option (Right to Buy) | −16,217 | 38,783 | D |
| 2025-01-24 | Exercise or conversion : show line 10 in the form 10b5-1 Stock Option (Right to Buy) | −22,468 | 16,315 | D |
| 2025-01-27 | Exercise or conversion : show line 11 in the form 10b5-1 Stock Option (Right to Buy) | −16,315 | 0 | D |
Loading xslF345X05/ownership.xml…